Lepu Biopharma says Phase III CLARITY-Gastric01 trial meets overall survival endpoint for CMG901 in late-line gastric cancer

• Lepu Biopharma reported positive top-line results from the global Phase III CLARITY-Gastric01 trial of CMG901 (AZD0901) in advanced CLDN18.2-positive disease.
• The study showed a statistically significant, clinically meaningful overall survival benefit in later-line patients versus investigator’s choice therapy.
• Progression-free survival trended better in the broader later-line population but missed statistical significance.
• No new safety signals were identified; tolerability matched the known profile of the drug.
• The announcement did not specify whether results were previously presented or when they will be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260728-12258451), on July 28, 2026, and is solely responsible for the information contained therein.